Scholar Rock Holding (SRRK) Non Operating Income (2017 - 2026)
Scholar Rock Holding's quarterly Non Operating Income came in at -$790000.0 in Q1 2026, down 1695.45% year-on-year from $49515.7 in Q1 2025, and down 1195.08% quarter-over-quarter from -$61000.0 in Q4 2025.
Scholar Rock Holding has reported Non Operating Income for 10 years, with the latest figure at -$790000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 1695.45% year-over-year to -$790000.0; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 69.61% YoY), and the FY2025 full-year result was -$301000.0, down 105.23% from the prior year.
- Non Operating Income for Q1 2026 stood at -$790000.0, down from -$61000.0 in the prior quarter.
- The five-year high for Non Operating Income was $2.9 million in Q4 2024, with the low at -$1.0 million in Q1 2022.
- Average Non Operating Income over 5 years is $700529.4, with a median of $990000.0 recorded in 2024.
- Year-over-year, Non Operating Income soared 313.27% in 2022 and tumbled 1695.45% in 2026.
- Tracing SRRK's Non Operating Income over 5 years: stood at $1.2 million in 2022, then surged by 62.49% to $1.9 million in 2023, then soared by 52.31% to $2.9 million in 2024, then slumped by 102.1% to -$61000.0 in 2025, then tumbled by 1195.08% to -$790000.0 in 2026.
- The last three Non Operating Income figures came in at -$790000.0 (Q1 2026), -$61000.0 (Q4 2025), and -$69000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | -790,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -790,000.00 |
| Dec 31, 2025 | -61,000.00 |
| Sep 30, 2025 | -69,000.00 |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | -44,000.00 |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | -38,000.00 |
| Jun 30, 2024 | 990,000.00 |
| Mar 31, 2024 | 1.57 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Sep 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.17 Mn |
| Sep 30, 2022 | 565,000.00 |
| Jun 30, 2022 | -853,000.00 |
| Mar 31, 2022 | -1.02 Mn |
| Dec 31, 2021 | -550,000.00 |
| Sep 30, 2021 | -430,000.00 |
| Jun 30, 2021 | -434,000.00 |
| Mar 31, 2021 | -464,000.00 |
| Dec 31, 2020 | -467,000.00 |
| Sep 30, 2020 | 57,000.00 |
| Jun 30, 2020 | 181,000.00 |
| Mar 31, 2020 | 624,000.00 |
| Dec 31, 2019 | 774,000.00 |
| Sep 30, 2019 | 959,000.00 |
| Jun 30, 2019 | 861,000.00 |
| Mar 31, 2019 | 948,000.00 |
| Dec 31, 2018 | 594,000.00 |
| Sep 30, 2018 | 472,000.00 |
| Jun 30, 2018 | 177,000.00 |
| Mar 31, 2018 | 124,000.00 |
| Dec 31, 2017 | 1,000.00 |
| Sep 30, 2017 | 4,000.00 |
| Jun 30, 2017 | -2,000.00 |